Victrex plc with ticker (LON:VCT) now has a potential upside of 29.4% according to JP Morgan Cazenove.
JP Morgan Cazenove set a target price of 1,680 GBX for the company, which when compared to the Victrex plc share price of 1,298 GBX at opening today (05/04/2024) indicates a potential upside of 29.4%. Trading has ranged between 1,152 (52 week low) and 1,716 (52 week high) with an average of 114,634 shares exchanging hands daily. The market capitalisation at the time of writing is £1,134,935,487.
Victrex plc is a United Kingdom-based holding company. The principal activity of the Company is the manufacture and sale of high-performance polymers. The Company develops solutions in polyetheretherketone (PEEK) and polyaryletherketone (PAEK) based polymers and selects semi-finished and finished parts. The Company operates through two segments: Sustainable Solutions and Medical. The Sustainable Solutions segment focuses on its energy and industrial, value-added resellers (VAR), automotive, aerospace and electronics markets. The Medical segment is focused on providing specialist solutions for medical device manufacturers. The Company’s subsidiaries include Victrex Manufacturing Limited, Invibio Limited, Invibio Knees Limited, Invibio Device Component Manufacturing Limited and Juvora Limited.
Victrex plc 29.4% potential upside indicated by JP Morgan Cazenove
- Written by: Charlotte Edwards
Latest Company News
Victrex has announced board and Executive Committee changes, including a planned CFO departure, new appointments and director retirement dates.
Victrex reported 18% third-quarter revenue growth, supported by higher volumes, and said full-year guidance remains unchanged.
Victrex reported H1 2026 revenue growth of 1% to £147.1m on 6% higher sales volumes, while underlying profit before tax fell 18% to £19.0m due to sales mix, pricing and currency impacts.
Victrex reported a 4% decline in Q1 FY2026 sales volumes, with growth in Energy & Industrial offset by weaker demand in Transport, VARs and Medical.
Victrex plc has announced the appointment of James Routh as CEO, effective 1 January 2026. He will succeed Jakob Sigurdsson, who will remain on the Board to ensure a smooth transition before stepping down following the company’s AGM on 6 February 2026.
Victrex plc (LON:VCT) reports strong H1 2025 results, showcasing a 16% sales volume increase. Explore key insights on its performance and future strategies.
